Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC.
Pan C, Duan H, Wu Y, Zhu C, Yi C, Duan Y, Lu D, Guo C, Wu D, Wang Y, Fu X, Xu J, Chen Y, Luo M, Tian W, Pan T, Xu W, Zhang S, Huang J.
Pan C, et al. Among authors: xu w, xu j.
Int J Oncol. 2020 Oct;57(4):939-955. doi: 10.3892/ijo.2020.5103. Epub 2020 Jul 27.
Int J Oncol. 2020.
PMID: 32945394
Free PMC article.